ALEXZA PHARMACTCLS INC's gross profit margin for the fourth quarter of its fiscal year 2014 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ALEXZA PHARMACTCLS INC is extremely liquid. Currently, the Quick Ratio is 3.03 which clearly shows the ability to cover any short-term cash needs. The company managed to increase its liquidity from the same period a year ago, despite already having strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 115.44% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY14||Q4 FY13|
|Net Sales ($mil)||1.45||1.31|
|Net Income ($mil)||-6.71||-5.69|
|Balance Sheet||Q4 FY14||Q4 FY13|
|Cash & Equiv. ($mil)||34.77||25.88|
|Total Assets ($mil)||61.56||47.07|
|Total Debt ($mil)||63.77||11.52|
|Profitability||Q4 FY14||Q4 FY13|
|Gross Profit Margin||-439.27||-652.79|
|Return on Assets||-59.66||-84.15|
|Return on Equity||0.0||0.0|
|Debt||Q4 FY14||Q4 FY13|
|Share Data||Q4 FY14||Q4 FY13|
|Shares outstanding (mil)||19.41||17.28|
|Div / share||0.0||0.0|
|Book value / share||-2.66||-1.39|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||38392.0||160688.0|
SELL. This stock?s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The current price-to-sales ratio is well above the S&P 500 average and above the industry average, indicating a premium.
|ALXA NM||Peers 32.75||ALXA NM||Peers 45.92|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ALXA's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ALXA's P/CF is negative making the measure meaningless.
|ALXA NM||Peers 17.68||ALXA NA||Peers 1.28|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ALXA's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ALXA NM||Peers 8.21||ALXA 13.70||Peers 9.32|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ALXA's P/B is negative making this valuation measure meaningless.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ALXA is expected to have an earnings growth rate that significantly exceeds its peers.
|ALXA 6.98||Peers 6.64||ALXA -88.38||Peers 11.98|
Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ALXA is trading at a valuation on par with its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ALXA significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV